A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood
Recruiting
Observational Study
Colorectal Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 350 (estimated)
- Sponsor
- Peking University Shougang Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This multi-center study aims to develop a precise predictive model for colorectal cancer (CRC) recurrence and metastasis based on multi-omics analysis of portal vein blood. Despite advances in surgical treatments, approximately 40% of CRC patients experience tumor recurrence or metastasis post-surgery, with 80-90% of metastases being unresectable. The study will include stage I-IV CRC patients and…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age 18 years or older
* Histologically confirmed stage I-IV colorectal cancer (CRC)
* Availability of pre-operative and intra-operative blood samples (portal vein and peripheral blood) and primary tumor tissue samples
* No neoadjuvant therapy before surgery
Exclusion Criteria…
Contacts